OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
960054

Qomel Co

PharmaceuticalsVerified

Qomel Co has a fully diluted share count of 7,000,000 shares, with no difference between basic and diluted shares outstanding, indicating no immediate dilution pressure from stock options or convertible securities. However, the company's liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and return metrics are not available in the current valuation snapshot, making it difficult to compare with industry_config preferred metrics or cohort medians. Without recent financial data on margins, ROIC, or EBITDA, a detailed assessment of its profitability is not possible at this time. Qomel Co's revenue is concentrated in its domestic market, with no disclosed international operations or segment breakdowns. This lack of geographic diversification may expose the company to regulatory and economic risks specific to Japan. The company's growth trajectory is unclear due to the absence of outlook data and revenue history. Without forward-looking guidance or historical performance metrics, it is difficult to assess the company's potential for future expansion or contraction. The risk assessment indicates a low level of dilution risk, but the company's liquidity risk remains unassessed. The absence of balance-sheet inputs and no going-concern language in source documents raises concerns about the company's financial health and ability to meet short-term obligations. Recent events and filings for Qomel Co are not available in the current dataset, limiting the ability to assess any recent strategic moves, product launches, or regulatory changes that may impact the company's performance.

30-day price · 9600-0.52 (-1.1%)
Low$47.00High$54.00Close$48.98As of14 May, 00:00 UTC
Profile
CompanyQomel Co
Ticker9600.SE
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Qomel Co is a Japanese pharmaceutical company that develops and markets a range of prescription drugs, primarily in the domestic market.

Classification. Qomel Co is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry, with a confidence level of 0.92.

Qomel Co has a fully diluted share count of 7,000,000 shares, with no difference between basic and diluted shares outstanding, indicating no immediate dilution pressure from stock options or convertible securities. However, the company's liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and return metrics are not available in the current valuation snapshot, making it difficult to compare with industry_config preferred metrics or cohort medians. Without recent financial data on margins, ROIC, or EBITDA, a detailed assessment of its profitability is not possible at this time. Qomel Co's revenue is concentrated in its domestic market, with no disclosed international operations or segment breakdowns. This lack of geographic diversification may expose the company to regulatory and economic risks specific to Japan. The company's growth trajectory is unclear due to the absence of outlook data and revenue history. Without forward-looking guidance or historical performance metrics, it is difficult to assess the company's potential for future expansion or contraction. The risk assessment indicates a low level of dilution risk, but the company's liquidity risk remains unassessed. The absence of balance-sheet inputs and no going-concern language in source documents raises concerns about the company's financial health and ability to meet short-term obligations. Recent events and filings for Qomel Co are not available in the current dataset, limiting the ability to assess any recent strategic moves, product launches, or regulatory changes that may impact the company's performance.
Key takeaways
  • Qomel Co has no immediate dilution pressure as basic and diluted shares are equal.
  • The company's liquidity risk is unassessed due to missing balance-sheet data.
  • No profitability metrics are available for comparison with industry benchmarks.
  • Revenue concentration in Japan may expose the company to localized economic and regulatory risks.
  • Growth trajectory and future performance are unclear due to the absence of outlook data.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySAR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$61.2M$8.3M$6.1M$6.2M
FY-3$77.7M$15.1M$12.7M$12.8M
FY-2$105.5M$20.6M$17.6M$5.7M
FY-1$124.2M$26.2M$22.0M$2.0M
FY0$132.2M$20.0M$15.0M-$31.8M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$52.1M$26.0M$6.4M
FY-3$70.3M$32.6M$25.4M
FY-2$99.1M$45.5M$11.4M
FY-1$185.3M$105.0M$17.2M
FY0$218.6M$119.9M$20.9M
PeriodOCFCapExFCFSBC
FY-4-$289.6k-$7.8k$6.2M
FY-3$24.9M-$52.5k$12.8M
FY-2-$4.4M-$12.1M$5.7M
FY-1-$4.6M-$20.1M$2.0M
FY0$21.5M-$47.0M-$31.8M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
Metric9600Activity
Op margin7.7% medp25 -2.4% · p75 15.5%
Net margin5.9% medp25 -3.8% · p75 12.8%
Gross margin45.5% medp25 31.1% · p75 62.9%
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-7.0% medp25 -14.9% · p75 -3.2%
Debt / equity25.0% medp25 3.8% · p75 63.3%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 10:27 UTC#ec799750
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 05:15 UTCJob: 0d7cd641